10-Q: CNBX Pharmaceuticals Reports Q1 2025 Results, Cites Reduced Operating Expenses and Ongoing Going Concern Challenges

Sentiment:

Quarterly Report 13 January 2025 8:25 AM

📋All filings for Cnbx Pharmaceuticals INC

CNBX Pharmaceuticals reported a net loss of $34,352 for the quarter ended November 30, 2024, with reduced operating expenses and ongoing concerns about its ability to continue as a going concern.

Capital raiseThe company has stated that it will need to raise funds to pay for its expenses.The company may have to borrow money from shareholders, issue equity, or enter into a strategic arrangement with a third party.There is no assurance that additional capital will be available to the company.

Worse than expectedThe company's net loss, while reduced, is still significant, and the company's cash position has deteriorated.The company's operating expenses, while reduced, are still high relative to its cash reserves.The company's accumulated deficit and going concern warning indicate a precarious financial situation.

Summary

CNBX Pharmaceuticals reported a net loss of $34,352 for the three months ended November 30, 2024, a significant decrease from the $178,523 loss in the same period of 2023.
Operating expenses decreased substantially to $36,837 from $261,337 year-over-year, primarily due to reduced general and administrative expenses and a pause in research and development activities.
The company's cash position decreased to $17,339 as of November 30, 2024, compared to $26,416 at the end of the previous quarter and $81,647 at the end of the same quarter in 2023.
The company has a significant accumulated deficit of $24,988,752 and faces substantial doubt about its ability to continue as a going concern.
CNBX is a pre-clinical stage biopharmaceutical company focused on developing innovative medicines in oncology, with a current focus on colorectal cancer.
The company's lead drug candidate, RCC-33, is being developed for colon cancer treatment, with plans to start first-in-human Phase I/II clinical trials in 2024.
The company expects to incur a minimum of $120,000 in expenses over the next twelve months and will need to raise additional capital to fund operations.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position, a going concern warning, and a need for additional capital, which are all negative indicators. While operating expenses have been reduced, the overall outlook is concerning.

Positives

The company significantly reduced its net loss for the quarter compared to the same period last year.
Operating expenses were substantially reduced, indicating cost-cutting measures.
The company is progressing with its drug candidate, RCC-33, and plans to start clinical trials.

Negatives

The company's cash balance has decreased significantly.
The company has a substantial accumulated deficit.
There is substantial doubt about the company's ability to continue as a going concern.
The company has paused its research operations, which may impact future development.

Risks

The company's ability to continue as a going concern is uncertain due to its financial losses and limited cash reserves.
The company needs to raise additional capital to fund its operations, and there is no assurance that it will be able to do so.
The company's research and development activities have been paused, which could delay the development of its drug candidates.
The company has significant debt obligations, including convertible loans and related party payables.
The company's financial statements contain a going concern warning from its independent auditors.

Future Outlook

The company plans to start first-in-human Phase I/II clinical trials for its lead drug candidate, RCC-33, in 2024. The company expects to incur a minimum of $120,000 in expenses over the next twelve months and will need to raise additional capital to fund operations.

Management Comments

Management has stated that the company's ability to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan.
Management has acknowledged the need to raise funds to pay for expenses, potentially through borrowing from shareholders, issuing equity, or entering into a strategic arrangement with a third party.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on oncology and specifically colorectal cancer. The development of novel therapies for cancer is a high-risk, high-reward endeavor, with significant regulatory hurdles and clinical trial requirements. The company's focus on a first-in-class therapy for colon cancer positions it in a potentially lucrative market, but it faces significant challenges in securing funding and advancing its clinical programs.

Comparison to Industry Standards

CNBX's financial situation is concerning when compared to industry standards for biotech companies at a similar stage of development.
Many pre-clinical stage biotech companies rely on venture capital or strategic partnerships to fund their operations, and CNBX's reliance on convertible debt and related party loans is not typical.
The company's cash burn rate, while reduced, is still significant given its limited cash reserves, and the going concern warning is a major red flag.
Compared to companies like Celldex Therapeutics (CLDX) or Onconova Therapeutics (ONTV), which are also developing oncology therapies, CNBX's financial position appears weaker, and its path to commercialization is less clear.
While companies like these may have similar challenges in early-stage development, they often have stronger financial backing and more established clinical trial programs.

Related Party Transactions

The company paid $9,152 in salaries to two directors during the three months ending November 30, 2024.
The company has a balance outstanding payable to two directors, Gabriel Yariv and Eyal Barad, totaling $932,771.
The company has a balance outstanding of $223,645 payable to Cannabics, Inc.

Stakeholder Impact

Shareholders face significant risk due to the company's financial instability and going concern warning.
Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
Customers and suppliers may be affected by the company's uncertain future and potential delays in product development.
Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

The company plans to start first-in-human Phase I/II clinical trials for its lead drug candidate, RCC-33, in 2024.
The company needs to secure additional funding to continue operations and advance its clinical programs.

Key Dates

Date	Description
2004-09-15	CNBX Pharmaceuticals Inc. was incorporated in the State of Nevada.
2010-09-30	The company increased its authorized capital and effected a 20-for-1 reverse stock split.
2014-04-25	Cannabics, Inc. acquired a majority of the issued and outstanding common stock of the Company.
2014-05-21	The company changed its name to CNBX Pharmaceuticals Inc.
2014-06-03	The company's Board of Directors declared a two-to-one forward stock split.
2014-06-19	FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC.
2014-08-25	The company organized G.R.I.N. Ultra Ltd. as a wholly-owned subsidiary.
2020-12-16	The company entered into a Securities Purchase Agreement for a private placement of senior secured convertible notes.
2020-12-21	The company closed the first tranche of the senior secured convertible notes.
2021-02-22	The company closed the second tranche of the senior secured convertible notes.
2021-04-23	The company closed the third tranche of the senior secured convertible notes and entered into a senior secured promissory note.
2022-03-16	The company issued a demand promissory note.
2022-05-12	The company effected a reverse-split of its common stock on a 1:120 basis.
2022-06-15	The company entered into a Securities Purchase Agreement for the issuance of a Convertible Promissory Note.
2023-06-12	The company entered into a Securities Purchase Agreement for the issuance of a Convertible Promissory Note.
2023-10-13	The company entered into a Securities Purchase Agreement for the issuance of a Convertible Promissory Note.
2024-09-24	The company entered into a Securities Purchase Agreement for the issuance of a Convertible Promissory Note.
2024-11-30	End of the reporting period for the quarterly report.
2024-12-30	The company entered into a Securities Purchase Agreement for the issuance of a Promissory Note.
2025-01-12	The company had 31,111,352 shares of its Common Stock outstanding.
2025-01-13	Date of the report and certifications.

Keywords

Pharmaceuticals, Biotechnology, Oncology, Colorectal Cancer, Clinical Trials, Drug Development, Financial Results, Going Concern, Operating Expenses, Net Loss, Capital Raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.